Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

John T. Bates, Christopher J. Keefer, James C. Slaughter, Daniel W. Kulp, William R. Schief, James E. Crowe Jr.
  • Virology, April 2014, Elsevier
  • DOI: 10.1016/j.virol.2014.02.010

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr James E Crowe